Our Take
A well-funded bet on an unproven drug class, not yet a category win—Phase III failure rates remain high, and the market for male contraception has never materialized at scale despite decades of research.
Why it matters
Reversible male contraception has stalled in development for 30 years despite steady research investment. A successful Phase III could unlock regulatory approval and prove the market exists, but clinical failure is the base case.
Do this week
Reproductive health companies: audit your clinical trial pipeline for Phase III readiness in 2027 so you can position partnerships or licensing before results arrive.
Contraline closes $92.5M Series B for male contraceptive trials
Contraline, a Google Ventures-backed biotech firm, announced a $92.5 million Series B financing round co-led by RA Capital Management and BVF Partners. The company plans to use the capital to advance NES/T Gel, a daily topical male contraceptive, into Phase III trials, targeting enrollment in 2027 (per company statement).
NES/T combines Nestorone (a synthetic progestin already approved in female contraceptives) with testosterone. The goal is to suppress sperm production while maintaining normal testosterone levels. In a Phase IIb trial involving 462 couples, the drug showed efficacy, tolerability, and reversibility (per company-reported data).
Contraline is also developing ADAM, a non-hormonal, reversible device designed to block sperm transit while allowing fluid passage.
The financing round included participation from Lumira Ventures and others. Board members from lead investors include Iris van Alderwerelt van Rosenburgh (BVF Partners) and Laura Stoppel (RA Capital Management).
Male contraception remains a category without a winner
If Phase III succeeds, NES/T could become the first hormonal contraceptive approved for men. No reversible male birth control has reached the market in the United States despite 40 years of research funding and multiple clinical programs (academic record).
Investor framing emphasizes reproductive choice and male participation in family planning. Yet the historical pattern is instructive: previous Phase III male contraceptive trials have failed to meet primary endpoints, and commercial demand has been weak even when efficacy was demonstrated. The fact that $92.5M is now being deployed signals belief that the regulatory and market landscape has shifted, but does not confirm it.
The timing coincides with tightening abortion restrictions in 11 U.S. states and ongoing litigation over mifepristone accessibility. Whether this policy environment increases adoption of male contraception—or simply increases investor appetite for reproductive health solutions broadly—remains unclear.
Track Phase III enrollment and readiness before 2027 results
Clinical and commercial teams in fertility, family planning, and sexual health should monitor Contraline's Phase III protocol and enrollment milestones. Early dropouts or safety signals will emerge long before final readout. Partnership and licensing interest will spike once enrollment velocity is established.
Comparator analysis should include prior male contraceptive failures (e.g., the ITIM2 trial halted in 2016 for safety concerns) to calibrate realistic Phase III success probability.